Thomas Melendy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Melendy has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Le Yang
Department of Microbiology and Immunology, University at Buffalo, State University of New York, Buffalo, New York
31 shared publications - Steve Goodison
Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA
31 shared publications - Yijun Sun
University at Buffalo
31 shared publications - Li Tang
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York
30 shared publications - Runpu Chen
Department of Microbiology and Immunology, University at Buffalo, State University of New York, Buffalo, New York
30 shared publications Shu-Ru Kuo
Departments of Microbiology & Immunology and Biochemistry, and the Witebsky Center for Microbial Pathogenesis & Immunology, University at Buffalo, School of Medicine & Biomedical Sciences, Buffalo, NY 14214, United States
7 shared publications
Latest Publications
- 10 November 2026
- Published by Elsevier in Cancer Letters
Effective Targeting of p53-Mutant Colorectal and Pancreatic Cancers by Combinatorial Therapeutic Strategy
- 10 November 2026
- Published by Elsevier in Cancer Letters
Effective Targeting of p53-Mutant Colorectal and Pancreatic Cancers by Combinatorial Therapeutic Strategy
- Open Access
HaCaT Keratinocytes: A Differentiation-Competent Platform for Episomal Replication of HPV Type 11
Few differentiation-competent models exist to study early intra-nuclear processes of human papillomavirus (HPV) in keratinocytes. Early HPV DNA replication is usually studied by transfecting transformed or tumor-derived cell lines (C33A, HEK293/HEK293T, CIN612). While these lines support episome replication, their transformed state and oncogene expression can confound interpretation, and they do not undergo the normal keratinocyte differentiation required for the HPV life cycle. We therefore evaluated HaCaT, a spontaneously immortalized, non-transformed keratinocyte line with reversible differentiation, as a model for HPV episomal replication. We optimized culture conditions—particularly extracellular calcium—to toggle HaCaT cells between basal-like proliferation and differentiation, and refined transfection parameters to deliver plasmid vectors required for HPV11 episomal replication. HaCaT cells display differentiation-associated morphological changes and keratin marker expression comparable to primary keratinocytes. In transient luciferase-based origin replicon assays, HPV11 plasmid replicons showed origin-dependent replication in both undifferentiated and differentiated HaCaT cells. Because Ca2+-driven differentiation rewires keratinocyte nuclear organization, this Ca2+-controlled HaCaT system enables evaluation of early viral nuclear processes, including episomal replication and differentiation-associated increases in replication activity, in a nuclear architecture–dependent epithelial context without exogenous viral oncogenes or cellular transformation.
Open AccessHaCaT Keratinocytes: A Differentiation-Competent Platform for Episomal Replication of HPV Type 11
Few differentiation-competent models exist to study early intra-nuclear processes of human papillomavirus (HPV) in keratinocytes. Early HPV DNA replication is usually studied by transfecting transformed or tumor-derived cell lines (C33A, HEK293/HEK293T, CIN612). While these lines support episome replication, their transformed state and oncogene expression can confound interpretation, and they do not undergo the normal keratinocyte differentiation required for the HPV life cycle. We therefore evaluated HaCaT, a spontaneously immortalized, non-transformed keratinocyte line with reversible differentiation, as a model for HPV episomal replication. We optimized culture conditions—particularly extracellular calcium—to toggle HaCaT cells between basal-like proliferation and differentiation, and refined transfection parameters to deliver plasmid vectors required for HPV11 episomal replication. HaCaT cells display differentiation-associated morphological changes and keratin marker expression comparable to primary keratinocytes. In transient luciferase-based origin replicon assays, HPV11 plasmid replicons showed origin-dependent replication in both undifferentiated and differentiated HaCaT cells. Because Ca2+-driven differentiation rewires keratinocyte nuclear organization, this Ca2+-controlled HaCaT system enables evaluation of early viral nuclear processes, including episomal replication and differentiation-associated increases in replication activity, in a nuclear architecture–dependent epithelial context without exogenous viral oncogenes or cellular transformation.
- Open Access
A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers
SUMMARY: The tumor suppressor TP53 gene (p53) is mutated in most human malignancies; however, existing treatment options are largely ineffective, lack selectivity, and cause toxic side effects. To address these clinical problems, we developed a sequential triple-drug strategy for p53 mutant cancer cells. Here we show that a combination of a thymidine analogue (TAS102) plus PARP inhibitor (PARPi) promotes formation of DNA double-strand breaks (DSBs) and G2-arrest specifically in p53 mutant cancer cells. Transcriptome analysis revealed that TAS102-PARPi treatment of p53 mutant cells did not repress DNA replication but activated DSB repair and blocked the mitotic program, consistent with G2-arrest. In contrast, TAS102-PARPi treatment of normal p53 wild-type cells resulted in a temporal G1-arrest and rapid recovery of cell cycle capacity after drug withdrawal. In p53 mutant cancer cells, subsequent blocking of a G2-checkpoint kinase, such as WEE1, released these G2-arrested cells into mitosis, leading to massive cell death. Delayed administration of a G2-kinase inhibitor provides time for p53 wild-type cells to repair DNA, thereby minimizing toxicity to normal tissues. This sequential triple-drug strategy exhibited robust efficacy in preclinical models of colorectal and pancreatic cancers and was well tolerated in mice. Together, our findings illustrate a promising triple-drug strategy for targeting p53 mutant malignancies.
Open AccessA Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers
SUMMARY: The tumor suppressor TP53 gene (p53) is mutated in most human malignancies; however, existing treatment options are largely ineffective, lack selectivity, and cause toxic side effects. To address these clinical problems, we developed a sequential triple-drug strategy for p53 mutant cancer cells. Here we show that a combination of a thymidine analogue (TAS102) plus PARP inhibitor (PARPi) promotes formation of DNA double-strand breaks (DSBs) and G2-arrest specifically in p53 mutant cancer cells. Transcriptome analysis revealed that TAS102-PARPi treatment of p53 mutant cells did not repress DNA replication but activated DSB repair and blocked the mitotic program, consistent with G2-arrest. In contrast, TAS102-PARPi treatment of normal p53 wild-type cells resulted in a temporal G1-arrest and rapid recovery of cell cycle capacity after drug withdrawal. In p53 mutant cancer cells, subsequent blocking of a G2-checkpoint kinase, such as WEE1, released these G2-arrested cells into mitosis, leading to massive cell death. Delayed administration of a G2-kinase inhibitor provides time for p53 wild-type cells to repair DNA, thereby minimizing toxicity to normal tissues. This sequential triple-drug strategy exhibited robust efficacy in preclinical models of colorectal and pancreatic cancers and was well tolerated in mice. Together, our findings illustrate a promising triple-drug strategy for targeting p53 mutant malignancies.
- 28 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (18_Supplem) , B001
Abstract B001: Effective targeting p53 mutant pancreatic cancer by novel drug-combination strategy leveraging their DNA damage liabilities
Genetic alterations in p53 (TP53) are found in most solid malignancies, including pancreatic cancer (PANC). Mutant p53 (p53mut) contributes to cancer progression and metastasis. Existing therapeutic options for p53mut cancers are ineffective and cause toxic side effects, stressing the need for better therapies. To address these clinical problems, we developed a two-drug therapeutic strategy that selectively targets p53mut cancers. This novel strategy combines a thymidine analogue (trifluorothymidine (TFT), a component of TAS102, acting as an inducer of DNA damage), and an inhibitor of poly (ADP) ribose polymerase (PARPi) that works as an amplifier of DNA damage. Incorporation of TFT into DNA provokes post-replicative repair generating single-strand DNA break intermediates. Repair of these intermediates is assisted by PARP, while inhibition of PARP increases more lethal double-strand DNA breaks. In normal p53 wild-type (WT) cells, TAS102 and PARPi activate p53-dependent G1/S checkpoint, limiting DNA damage and promoting repair. In p53mut cells with compromised G1/S checkpoint, TAS102 and PARPi cooperate as the inducer-amplifier pair to increase lethal DNA breaks and cell death. The TAS102-PARPi strategy was validated in preclinical studies. Our first-in-human phase I study with TAS102-talazoparib regimen (NCT04511039) showed that this regimen is safe with promising efficacy. The current work investigated the mechanisms underlying the response to TAS102-PARPi regimen in p53mut cancer cells. Our data show that TAS102-PARPi induces the G2/M checkpoint mediated by ATR kinase in a p53-independent manner. ATR acts through the G2-checkpoint kinases (CHK1 and WEE1) to inactivate CDK1 and stop transition to mitosis. The transcriptome analysis showed that TAS102-PARPi treatment increased expression of Claspin and inactivated PLK1-driven mitotic pathway. Claspin is critical for activation of DNA damage and replication checkpoints by facilitating ATR-CHK1 signaling, whereas PLK1 mediates inactivation of the G2-checkpoint kinases and degradation of Claspin for normal cell cycle progression and re-entry into mitosis. Thus, the PLK1-Claspin network may play a key regulatory role in G2-checkpoint in response to TAS102-PARPi by restraining premature reentry into cell cycle of cells with unrepaired DNA. The next major question was whether TAS102-PARPi regimen can cooperate with drugs disrupting G2-checkpoint. New data show that the efficacy of TAS102-PARPi therapy is greatly enhanced by a sequential application of G2-kinase WEE1 inhibitor. Our data show that this sequential triple-drug strategy works in a synthetic-lethality manner to cause massive cell death in p53mut cancers. The triple-drug strategy greatly improved tumor control in PANC patient-derived xenografts with no signs of major toxicities to normal tissues. In summary, this study provides the scientific foundation for our novel sequential triple-drug strategy that demonstrates greater efficacy against pancreatic cancer with lower toxicity. Citation Format: Andrei Bakin, Mohammed Alruwaili, Ashley Guo, Thomas Melendy, Barbara Foster, Christos Fountzilas. Effective targeting p53 mutant pancreatic cancer by novel drug-combination strategy leveraging their DNA damage liabilities [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3):Abstract nr B001.
- 28 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (18_Supplem) , B001
Abstract B001: Effective targeting p53 mutant pancreatic cancer by novel drug-combination strategy leveraging their DNA damage liabilities
Genetic alterations in p53 (TP53) are found in most solid malignancies, including pancreatic cancer (PANC). Mutant p53 (p53mut) contributes to cancer progression and metastasis. Existing therapeutic options for p53mut cancers are ineffective and cause toxic side effects, stressing the need for better therapies. To address these clinical problems, we developed a two-drug therapeutic strategy that selectively targets p53mut cancers. This novel strategy combines a thymidine analogue (trifluorothymidine (TFT), a component of TAS102, acting as an inducer of DNA damage), and an inhibitor of poly (ADP) ribose polymerase (PARPi) that works as an amplifier of DNA damage. Incorporation of TFT into DNA provokes post-replicative repair generating single-strand DNA break intermediates. Repair of these intermediates is assisted by PARP, while inhibition of PARP increases more lethal double-strand DNA breaks. In normal p53 wild-type (WT) cells, TAS102 and PARPi activate p53-dependent G1/S checkpoint, limiting DNA damage and promoting repair. In p53mut cells with compromised G1/S checkpoint, TAS102 and PARPi cooperate as the inducer-amplifier pair to increase lethal DNA breaks and cell death. The TAS102-PARPi strategy was validated in preclinical studies. Our first-in-human phase I study with TAS102-talazoparib regimen (NCT04511039) showed that this regimen is safe with promising efficacy. The current work investigated the mechanisms underlying the response to TAS102-PARPi regimen in p53mut cancer cells. Our data show that TAS102-PARPi induces the G2/M checkpoint mediated by ATR kinase in a p53-independent manner. ATR acts through the G2-checkpoint kinases (CHK1 and WEE1) to inactivate CDK1 and stop transition to mitosis. The transcriptome analysis showed that TAS102-PARPi treatment increased expression of Claspin and inactivated PLK1-driven mitotic pathway. Claspin is critical for activation of DNA damage and replication checkpoints by facilitating ATR-CHK1 signaling, whereas PLK1 mediates inactivation of the G2-checkpoint kinases and degradation of Claspin for normal cell cycle progression and re-entry into mitosis. Thus, the PLK1-Claspin network may play a key regulatory role in G2-checkpoint in response to TAS102-PARPi by restraining premature reentry into cell cycle of cells with unrepaired DNA. The next major question was whether TAS102-PARPi regimen can cooperate with drugs disrupting G2-checkpoint. New data show that the efficacy of TAS102-PARPi therapy is greatly enhanced by a sequential application of G2-kinase WEE1 inhibitor. Our data show that this sequential triple-drug strategy works in a synthetic-lethality manner to cause massive cell death in p53mut cancers. The triple-drug strategy greatly improved tumor control in PANC patient-derived xenografts with no signs of major toxicities to normal tissues. In summary, this study provides the scientific foundation for our novel sequential triple-drug strategy that demonstrates greater efficacy against pancreatic cancer with lower toxicity. Citation Format: Andrei Bakin, Mohammed Alruwaili, Ashley Guo, Thomas Melendy, Barbara Foster, Christos Fountzilas. Effective targeting p53 mutant pancreatic cancer by novel drug-combination strategy leveraging their DNA damage liabilities [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3):Abstract nr B001.
- 13 June 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (12_Supplem) , P3-08
Abstract P3-08-27: Novel Combination Immune Therapy for Metastatic Breast Cancers leveraging weaknesses in DNA damage response in p53 Mutant cancer
Metastatic breast cancer (MBC) is a life-threatening disease with lowest 5-year survival rates in patients with metastatic triple-negative breast cancer (mTNBC). Most MBCs carry mutant p53 that drives cancer progression and metastasis in part by promoting the build-up of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), major immune suppressive cells in the immune environment. At present, there are no effective treatment options for p53-mutant BC, while existing chemotherapy-based treatments exhibit low selectivity for p53mut status and high frequency of adverse side effects. We developed a novel therapeutic strategy for selective damaging p53-mutant tumors addressing the limitations mentioned above. Our novel strategy for p53mut cancers uses two drugs, one acting as an inducer (TAS102) and the other an amplifier (PARP inhibitor, PARPi), to achieve selective damage to p53mut cancers. Thymidine nucleotide analogue TAS102 does not block DNA synthesis but activates post-replicative repair leading to DNA breaks, while PARPi blocks repair of these DNA lesions. The two-drug strategy showed high efficacy, without adverse effects, in preclinical cancer models. Our first-in-human phase I study with the two-drug TAS102-PARPi regimen for colon cancer (NCT04511039, PI: Fountzilas) did not identify major signs of toxicity and the preliminary efficacy is promising. The dose-expansion part of the study is actively accruing patients with one patient already attaining a partial radiographic response. The present work investigates the impact of the two-drug TAS102-PARPi regimen on the immune landscape in mice implanted with mTNBC tumor cells. We observed that TAS102-PARPi reduced tumor growth and metastases to the lungs and liver. The two-drug regimen reduced levels of MDSCs and TAMs and increased levels of lymphocytes, indicating that the regimen may positively cooperate with immunotherapy directed to enhance anti-tumor activity of T cells. Depletion of CD8+ T cells markedly reduced anti-tumor activity of the TAS102-PARPi regimen. Immunophenotyping showed that the two-drug therapy increased tumor infiltration by CD8+ T cells expressing immune-checkpoint receptors PD1 and LAG3. Testing the two-drug therapy in combination with antibodies blocking the inhibitory receptors anti-PD1 or anti-LAG3 showed a dramatic reduction in tumor growth and metastases. Together these results demonstrate that the two-drug TAS102-PARPi regimen can be combined with immune checkpoint blockade therapy for effective treatment of MBCs including mTNBCs. Citation Format: Ashley Guo, Priyanka Rajan, Mohammed Alruwaili, Joseph Barbi, Scott Abrams, Thomas Melendy, Christos Fountzilas, Andrei Bakin. Novel Combination Immune Therapy for Metastatic Breast Cancers leveraging weaknesses in DNA damage response in p53 Mutant cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-08-27.
- 13 June 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (12_Supplem) , P3-08
Abstract P3-08-27: Novel Combination Immune Therapy for Metastatic Breast Cancers leveraging weaknesses in DNA damage response in p53 Mutant cancer
Metastatic breast cancer (MBC) is a life-threatening disease with lowest 5-year survival rates in patients with metastatic triple-negative breast cancer (mTNBC). Most MBCs carry mutant p53 that drives cancer progression and metastasis in part by promoting the build-up of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), major immune suppressive cells in the immune environment. At present, there are no effective treatment options for p53-mutant BC, while existing chemotherapy-based treatments exhibit low selectivity for p53mut status and high frequency of adverse side effects. We developed a novel therapeutic strategy for selective damaging p53-mutant tumors addressing the limitations mentioned above. Our novel strategy for p53mut cancers uses two drugs, one acting as an inducer (TAS102) and the other an amplifier (PARP inhibitor, PARPi), to achieve selective damage to p53mut cancers. Thymidine nucleotide analogue TAS102 does not block DNA synthesis but activates post-replicative repair leading to DNA breaks, while PARPi blocks repair of these DNA lesions. The two-drug strategy showed high efficacy, without adverse effects, in preclinical cancer models. Our first-in-human phase I study with the two-drug TAS102-PARPi regimen for colon cancer (NCT04511039, PI: Fountzilas) did not identify major signs of toxicity and the preliminary efficacy is promising. The dose-expansion part of the study is actively accruing patients with one patient already attaining a partial radiographic response. The present work investigates the impact of the two-drug TAS102-PARPi regimen on the immune landscape in mice implanted with mTNBC tumor cells. We observed that TAS102-PARPi reduced tumor growth and metastases to the lungs and liver. The two-drug regimen reduced levels of MDSCs and TAMs and increased levels of lymphocytes, indicating that the regimen may positively cooperate with immunotherapy directed to enhance anti-tumor activity of T cells. Depletion of CD8+ T cells markedly reduced anti-tumor activity of the TAS102-PARPi regimen. Immunophenotyping showed that the two-drug therapy increased tumor infiltration by CD8+ T cells expressing immune-checkpoint receptors PD1 and LAG3. Testing the two-drug therapy in combination with antibodies blocking the inhibitory receptors anti-PD1 or anti-LAG3 showed a dramatic reduction in tumor growth and metastases. Together these results demonstrate that the two-drug TAS102-PARPi regimen can be combined with immune checkpoint blockade therapy for effective treatment of MBCs including mTNBCs. Citation Format: Ashley Guo, Priyanka Rajan, Mohammed Alruwaili, Joseph Barbi, Scott Abrams, Thomas Melendy, Christos Fountzilas, Andrei Bakin. Novel Combination Immune Therapy for Metastatic Breast Cancers leveraging weaknesses in DNA damage response in p53 Mutant cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-08-27.
- 21 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (8_Suppleme) , 663
Abstract 663: A novel combination immunotherapy for p53 mutant metastatic breast cancer leveraging vulnerabilities in the DNA damage response
Metastatic breast cancer (MBC) is a life-threatening disease with the lowest 5-year survival rates seen in patients with metastatic triple-negative breast cancer (TNBC). MBCs, including TNBCs, commonly carry mutations in the tumor suppressor p53. Mutant p53 (p53Mut) drives cancer progression and metastasis, in part, by promoting the accumulation of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), major enforcers of immune suppression in the tumor microenvironment (TME). At present, there are no effective treatment options for p53mut MBC, while existing chemotherapy-based treatments exhibit low selectivity for p53mut status and frequent adverse side effects. To address this clinical challenge, we developed a novel therapeutic strategy for the selective targeting of p53mut tumors. This novel strategy employs two drugs, one acting as an inducer (TAS102) and the other as an amplifier (PARP inhibitor, PARPi), to achieve selective and potent damage to p53mut tumors. Thymidine nucleotide analogue TAS102 does not block DNA synthesis but activates post-replicative repair leading to DNA breaks, while PARPi blocks repair of these DNA lesions. Post-replicative DNA repair results in DNA breaks and G2-arrest in p53mut cells. In contrast, p53WT cells accumulate in G1-phase and efficiently remove thymidine analogues. Our two-drug strategy showed high efficacy, without adverse effects, in preclinical cancer models of MBC. In this study, we further investigated the impact of the two-drug TAS102-PARPi regimen on the immune landscape in preclinical models of metastatic TNBC. We observed that the TAS102-PARPi combination reduced tumor growth and metastases in the lungs and liver. The two-drug regimen reduced the levels of MDSCs and TAMs, increased the levels of lymphocytes in the TME, and promoted CD8+ T cell-mediated anti-tumor activity that was abrogated by cell depletion. Immunophenotyping showed that the dual agent therapy increased the frequency of intra-tumoral CD8+ T cells expressing the immune checkpoint receptors PD-1 and LAG3, suggesting that the regimen may cooperate with immunotherapies targeting these molecules. Indeed, combining the dual agent therapy with anti-PD-1 or anti-LAG3 antibodies showed a further reduction in tumor growth and metastases. Together, these results demonstrate that the two-drug TAS102-PARPi regimen can be combined with immune checkpoint blockade for effective treatment of MBC, and potentially other p53-mutant cancers, like colorectal and pancreatic cancers. Citation Format: Andrei V. Bakin, Ashley Guo, Priyanka Rajan, Mohammed Alruwaili, Joseph Barbi, Scott I. Abrams, Thomas Melendy, Christos Fountzilas. A novel combination immunotherapy for p53 mutant metastatic breast cancer leveraging vulnerabilities in the DNA damage response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 663.
- 21 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (8_Suppleme) , 663
Abstract 663: A novel combination immunotherapy for p53 mutant metastatic breast cancer leveraging vulnerabilities in the DNA damage response
Metastatic breast cancer (MBC) is a life-threatening disease with the lowest 5-year survival rates seen in patients with metastatic triple-negative breast cancer (TNBC). MBCs, including TNBCs, commonly carry mutations in the tumor suppressor p53. Mutant p53 (p53Mut) drives cancer progression and metastasis, in part, by promoting the accumulation of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), major enforcers of immune suppression in the tumor microenvironment (TME). At present, there are no effective treatment options for p53mut MBC, while existing chemotherapy-based treatments exhibit low selectivity for p53mut status and frequent adverse side effects. To address this clinical challenge, we developed a novel therapeutic strategy for the selective targeting of p53mut tumors. This novel strategy employs two drugs, one acting as an inducer (TAS102) and the other as an amplifier (PARP inhibitor, PARPi), to achieve selective and potent damage to p53mut tumors. Thymidine nucleotide analogue TAS102 does not block DNA synthesis but activates post-replicative repair leading to DNA breaks, while PARPi blocks repair of these DNA lesions. Post-replicative DNA repair results in DNA breaks and G2-arrest in p53mut cells. In contrast, p53WT cells accumulate in G1-phase and efficiently remove thymidine analogues. Our two-drug strategy showed high efficacy, without adverse effects, in preclinical cancer models of MBC. In this study, we further investigated the impact of the two-drug TAS102-PARPi regimen on the immune landscape in preclinical models of metastatic TNBC. We observed that the TAS102-PARPi combination reduced tumor growth and metastases in the lungs and liver. The two-drug regimen reduced the levels of MDSCs and TAMs, increased the levels of lymphocytes in the TME, and promoted CD8+ T cell-mediated anti-tumor activity that was abrogated by cell depletion. Immunophenotyping showed that the dual agent therapy increased the frequency of intra-tumoral CD8+ T cells expressing the immune checkpoint receptors PD-1 and LAG3, suggesting that the regimen may cooperate with immunotherapies targeting these molecules. Indeed, combining the dual agent therapy with anti-PD-1 or anti-LAG3 antibodies showed a further reduction in tumor growth and metastases. Together, these results demonstrate that the two-drug TAS102-PARPi regimen can be combined with immune checkpoint blockade for effective treatment of MBC, and potentially other p53-mutant cancers, like colorectal and pancreatic cancers. Citation Format: Andrei V. Bakin, Ashley Guo, Priyanka Rajan, Mohammed Alruwaili, Joseph Barbi, Scott I. Abrams, Thomas Melendy, Christos Fountzilas. A novel combination immunotherapy for p53 mutant metastatic breast cancer leveraging vulnerabilities in the DNA damage response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 663.
- 21 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (8_Suppleme) , 5991
Abstract 5991: Novel triple-drug combination strategy for p53 mutant cancers leveraging their DNA damage response liabilities
Genetic alterations in the tumor suppressor p53 gene (TP53) are found in most solid malignancies, including colorectal (CRC), breast (BC), and pancreatic (PANC) cancers. Mutant p53 contributes to cancer progression and metastasis. Current therapeutic options show low selectivity for p53-mutant cancers and frequently exhibit high toxicity. To address this unmet clinical need, we developed a two-drug therapeutic strategy that selectively targets p53-mutant cancers. This novel strategy combines a thymidine analogue TAS102, acting as an inducer of DNA damage, and PARP inhibitor (PARPi) that works as an amplifier of DNA damage. Our two-drug therapeutic strategy showed greater efficacy in p53 mutant cancer models (including patient-derived xenografts (PDXs)) than either drug alone. The two-drug regimen was well tolerated in animal preclinical PDX and cell-derived xenograft models. This two-drug strategy is now being tested in Phase I clinical trial for patients with advanced CRC (NCT04511039). Clinical data showed no major signs of toxicity and increased progression-free survival compared to TAS102 alone. Mechanistically, the incorporation of thymidine analogues into DNA provokes post-replicative repair, generating single-strand DNA break intermediates. Repair of these intermediates is assisted by PARP, while inhibition of PARP increases more lethal double-strand DNA breaks. Cells with p53 wild-type (p53WT) respond with G1 and G2 -checkpoint arrest and efficiently remove thymidine analogues. In contrast, p53 mutant cells, lacking the G1 checkpoint, accumulate in G2 with lethal DNA breaks. The current work investigated the mechanism of the DNA damage response (DDR) and the G2 checkpoint induction in response to the TAS102-PARPi regimen. Analysis of DDR signaling showed that the G2 checkpoint in response to TAS102-PARPi is mediated by ATR kinase that acts through CHK1 and WEE1 kinases. We next examined a drug combination using the two-drug TAS102-PARPi regimen and the G2 checkpoint kinase inhibitors together. The concurrent triple-drug regimen showed high toxicity to non-tumor cells and cancer cells. In contrast, a sequential drug regimen, the two-drug treatment followed by G2-checkpoint inhibitors demonstrated selective toxicity against p53 mutant cancer cells. This sequential triple-drug regimen was further examined in preclinical CRC model in mice. The triple-drug regimen showed substantially greater anti-tumor activity in p53 mutant CRC xenograft model without adverse side effects (based on mouse body weight and peripheral blood analysis). Based on these preclinical studies, we propose a novel triple-drug therapeutic strategy for p53 mutant cancers that has strong potential to improve cancer treatment and meaningfully impact the health of cancer patients. Citation Format: Mohammed M. Alruwaili, Aidan Mazierski, Erica Norris, Kyeong Beom Jo, Yanqi Guo, Priyanka Rajan, Henry Withers, Thomas Melendy, Christos Fountzilas, Andrei Bakin. Novel triple-drug combination strategy for p53 mutant cancers leveraging their DNA damage response liabilities [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5991.
- 21 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (8_Suppleme) , 5991
Abstract 5991: Novel triple-drug combination strategy for p53 mutant cancers leveraging their DNA damage response liabilities
Genetic alterations in the tumor suppressor p53 gene (TP53) are found in most solid malignancies, including colorectal (CRC), breast (BC), and pancreatic (PANC) cancers. Mutant p53 contributes to cancer progression and metastasis. Current therapeutic options show low selectivity for p53-mutant cancers and frequently exhibit high toxicity. To address this unmet clinical need, we developed a two-drug therapeutic strategy that selectively targets p53-mutant cancers. This novel strategy combines a thymidine analogue TAS102, acting as an inducer of DNA damage, and PARP inhibitor (PARPi) that works as an amplifier of DNA damage. Our two-drug therapeutic strategy showed greater efficacy in p53 mutant cancer models (including patient-derived xenografts (PDXs)) than either drug alone. The two-drug regimen was well tolerated in animal preclinical PDX and cell-derived xenograft models. This two-drug strategy is now being tested in Phase I clinical trial for patients with advanced CRC (NCT04511039). Clinical data showed no major signs of toxicity and increased progression-free survival compared to TAS102 alone. Mechanistically, the incorporation of thymidine analogues into DNA provokes post-replicative repair, generating single-strand DNA break intermediates. Repair of these intermediates is assisted by PARP, while inhibition of PARP increases more lethal double-strand DNA breaks. Cells with p53 wild-type (p53WT) respond with G1 and G2 -checkpoint arrest and efficiently remove thymidine analogues. In contrast, p53 mutant cells, lacking the G1 checkpoint, accumulate in G2 with lethal DNA breaks. The current work investigated the mechanism of the DNA damage response (DDR) and the G2 checkpoint induction in response to the TAS102-PARPi regimen. Analysis of DDR signaling showed that the G2 checkpoint in response to TAS102-PARPi is mediated by ATR kinase that acts through CHK1 and WEE1 kinases. We next examined a drug combination using the two-drug TAS102-PARPi regimen and the G2 checkpoint kinase inhibitors together. The concurrent triple-drug regimen showed high toxicity to non-tumor cells and cancer cells. In contrast, a sequential drug regimen, the two-drug treatment followed by G2-checkpoint inhibitors demonstrated selective toxicity against p53 mutant cancer cells. This sequential triple-drug regimen was further examined in preclinical CRC model in mice. The triple-drug regimen showed substantially greater anti-tumor activity in p53 mutant CRC xenograft model without adverse side effects (based on mouse body weight and peripheral blood analysis). Based on these preclinical studies, we propose a novel triple-drug therapeutic strategy for p53 mutant cancers that has strong potential to improve cancer treatment and meaningfully impact the health of cancer patients. Citation Format: Mohammed M. Alruwaili, Aidan Mazierski, Erica Norris, Kyeong Beom Jo, Yanqi Guo, Priyanka Rajan, Henry Withers, Thomas Melendy, Christos Fountzilas, Andrei Bakin. Novel triple-drug combination strategy for p53 mutant cancers leveraging their DNA damage response liabilities [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5991.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S14-15 from Prostate Cancer Progression Modeling Provides Insight into Dynamic Molecular Changes Associated with Progressive Disease States
GSE46691 disease-related genes, paths.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S14-15 from Prostate Cancer Progression Modeling Provides Insight into Dynamic Molecular Changes Associated with Progressive Disease States
GSE46691 disease-related genes, paths.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Prostate Cancer Progression Modeling Provides Insight into Dynamic Molecular Changes Associated with Progressive Disease States
Data, methods and softwares used.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Prostate Cancer Progression Modeling Provides Insight into Dynamic Molecular Changes Associated with Progressive Disease States
Data, methods and softwares used.